1. Pellerito L, Nagy L (2002) Organotin(IV)n+ complexes formed with biologically active ligands: equilibrium and structural studies, and some biological aspects. Coord Chem Rev 224:111–150. doi: 10.1016/S0010-8545(01)00399-X
2. Gielen M, Tiekink ERT (eds) (2005) Metallotherapeutic D and metal-based diagnostic agents: 50SnTin compounds and their therapeutic potential. Wiley, Chichester, pp 421–439
3. Li Q, Yang P, Wang H, Guo M (1996) Diorganotin(IV) antitumor agent. (C2H5)2SnCl2 (phen)/nucleotides aqueous and solid-state coordination chemistry and its DNA binding studies. J Inorg Chem 15;64(3):181–195
4. Crowe AJ (1987) The chemotherapeutic properties of tin compounds. Drugs Future 12:255–275
5. Gielen M, Willem R, Bouhdid A, De Vos D, Kuiper CM, Veerman G et al (1995) In vitro antiproliferation effects, toxicity profiles in vivo in mice and antitumor activity in tumor bearing mice of five diorganotin compounds. In Vivo 9:59–64